InMode Ltd. (INMD)
- Previous Close
17.02 - Open
17.03 - Bid 17.02 x 500
- Ask 17.07 x 100
- Day's Range
16.87 - 17.32 - 52 Week Range
16.82 - 48.25 - Volume
397,502 - Avg. Volume
1,557,467 - Market Cap (intraday)
1.444B - Beta (5Y Monthly) 2.16
- PE Ratio (TTM)
7.42 - EPS (TTM)
2.30 - Earnings Date May 2, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
27.60
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokne'am, Israel.
www.inmodemd.comRecent News: INMD
Performance Overview: INMD
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: INMD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: INMD
Valuation Measures
Market Cap
1.44B
Enterprise Value
707.63M
Trailing P/E
7.40
Forward P/E
6.89
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.97
Price/Book (mrq)
1.83
Enterprise Value/Revenue
1.44
Enterprise Value/EBITDA
3.61
Financial Highlights
Profitability and Income Statement
Profit Margin
40.22%
Return on Assets (ttm)
16.22%
Return on Equity (ttm)
29.50%
Revenue (ttm)
492.05M
Net Income Avi to Common (ttm)
197.92M
Diluted EPS (ttm)
2.30
Balance Sheet and Cash Flow
Total Cash (mrq)
741.6M
Total Debt/Equity (mrq)
1.15%
Levered Free Cash Flow (ttm)
105.23M